CarbGeM Selected for METI's Grant

CarbGeM Selected for METI’s FY2025 Healthcare Industry International Expansion Promotion Program Grant

— Exploring the Feasibility of DX/AI Solutions for Bacterial Infections in India —
— Promoting Sustainable International Expansion through the Fusion of Infection Control and Medical DX —


CarbGeM Inc. (Headquarters: Shibuya-ku, Tokyo; CEO: Masakazu Nakajima; hereinafter “CarbGeM”) is pleased to announce that its project, “Feasibility Study on the Introduction and Market Fit of DX/AI Solutions for Bacterial Infections in India” (hereinafter “the Project”), has been selected for the FY2025 Healthcare Industry International Expansion Promotion Program (hereinafter “the Program”), organized by the Ministry of Economy, Trade and Industry (METI) and administered by Medical Excellence JAPAN (MEJ).


About the Healthcare Industry International Expansion Promotion Program

This program supports feasibility studies and demonstration projects aimed at the strategic overseas expansion of Japan’s highly competitive healthcare products, services, and technologies. By providing subsidies to healthcare institutions and companies, the program seeks to accelerate the global deployment of Japanese healthcare solutions.


About CarbGeM’s Project

CarbGeM’s initiative will conduct a feasibility study focusing on implementing DX/AI-powered solutions for the diagnosis of bacterial infections in India. The project aims to assess the adaptability and market potential of AI-based diagnostic imaging technologies and a cloud-based AI image analysis platform, and to develop a phased implementation model in alignment with India’s national strategy for AMR (Antimicrobial Resistance). In addition, CarbGeM explores possibilities for joint ventures with local partners.

This initiative seeks to contribute to strengthening India’s infectious disease control efforts, addressing medical personnel shortages, and improving diagnostic accuracy nationwide.

Please refer to the list of selected companies published on the MEJ website.
(リンク ») (Japanese website only)
________________________________________

About CarbConnect® – A Cloud-Based AI Image Analysis Platform

CarbConnect® is a cloud-based digital platform developed by CarbGeM that enables real-time uploading, analysis, and sharing of medical and research images.
Key Features:

• Real-Time AI Analysis: Enables immediate image analysis and upload directly from the field
• Secure Cloud Storage: Accessible from remote and multi-site environments
• Optimized for Medical and Research Use: Boosts operational efficiency with high-precision AI image analysis

▶ Learn more: (リンク »)
________________________________________

About BiTTE®-iE – AI-Powered Microbial Estimation Software (Research Use Only)

BiTTE®-iE is a non-medical AI software that estimates bacteria within 10 seconds using AI-based analysis of Gram-stained images. It is designed for research purposes and aids in the early-stage identification of bacterial species, accelerating decision-making in both clinical and research settings.

Key Features:

• High-Accuracy AI Estimation: Matches expert-level performance in identifying major Gram-positive and Gram-negative bacteria
• Fully Automated: No manual operation required—images are analyzed instantly by AI
• Mobile-Compatible: Available globally via App Store and Google Play in over 170 countries
• Purpose-Built for Research: Suitable for education, training, and research use (not for clinical diagnostics)

▶ Learn more: (リンク »)
________________________________________

Future Outlook

CarbGeM will continue to promote the deployment of medical DX powered by advanced AI technologies in the Global South, including regions across Asia and Africa. Through international collaboration and open innovation, the company aims to contribute to reducing healthcare disparities and building sustainable healthcare infrastructure worldwide.
________________________________________

About CarbGeM Inc.

CarbGeM is a pioneering technology company committed to advancing diagnostic support, research efficiency, and quality control through innovative software as a medical device (SaMD) and AI-based platforms. We tackle societal challenges such as skilled workforce shortages and regional disparities by providing accurate and rapid solutions for medical and industrial fields.

The company also promotes global cooperation to address challenges such as antimicrobial resistance (AMR), leveraging digital platforms to empower collaboration between researchers and medical professionals.

CarbGeM has been recognized with numerous awards, including the Tokyo Social Innovation Tech Award 2024, and actively engages in open innovation with leading domestic and international research institutions, as well as government-academic-industry partnerships.

• Headquarters: 5-13-1 Jinnan, Shibuya-ku, Tokyo, Japan
• CEO: Masakazu Nakajima
• Website: (リンク »)